Publisher middleman DeepDyve has launched a five-minute "freemium" service that CEO William Park says saves researchers money, and prevents the hassle of buying off-target research. Publishers such as Wiley support the service through cross-promotions on their websites.
Missing documents allegedly kept a review of Tamiflu from conclusively examining the drug's efficacy. Are reviews marred by publication and reporting biases? What can be done to make assessments more robust?